Avalo Therapeutics, Inc. · NASDAQ:AVTX

Sullivan Christopher Ryan sold 47,000 Avalo Therapeutics, Inc. shares (Form 4)

Traded May 6, 2026 · Filed May 7, 2026

On May 6, 2026, Sullivan Christopher Ryan (Chief Financial Officer) sold 47,000 Avalo Therapeutics, Inc. shares at an average US$20.18 for US$949K under a trading plan, leaving 423 shares. Filed May 7, 2026 (Form 4).

Sold
47,000 shares
Price
US$20.18 average (US$18.55 to US$22.57)
Value
US$949K
Holding after
423 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Chief Financial Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
May 6, 2026Common StockOption exercise47,000US$8.0447,423Direct
May 6, 2026Common StockSale13,834US$18.5533,589Direct
May 6, 2026Common StockSale12,347US$19.2821,242Direct
May 6, 2026Common StockSale2,700US$20.7618,542Direct
May 6, 2026Common StockSale9,219US$21.379,323Direct
May 6, 2026Common StockSale8,900US$22.57423Direct

Source

View original at SEC

Related